Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peer Tfelt-Hansen

Showing results (71-80 of 110) with videos related to

Pageof 11
Sort By:
Pharmacology Research & Perspectives|July 15, 2015
The putative P-gp inhibitor telmisartan does not affect the transcellular permeability and cellular uptake of the calcium channel antagonist verapamil in the P-glycoprotein expressing cell line MDCK II MDR1Lasse Saaby, Peer Tfelt-Hansen, Birger Brodin
Ugeskrift for Laeger|October 23, 2008
[Clinical symptoms and pathophysiology of migraine]Peer Tfelt-Hansen, Messoud Ashina, Jes Olesen
Headache|May 22, 2009
Cluster headache and auraKarl Ekbom, Elisabet Waldenlind, Peer Tfelt-Hansen
The Journal of Headache and Pain|May 15, 2007
Contractile responses to ergotamine and dihydroergotamine in the perfused middle cerebral artery of ratPeer Tfelt-Hansen, Elisabeth Nilsson, Lars Edvinsson
Cephalalgia : an International Journal of Headache|May 13, 2021
Critique of the analysis of the time course for the antimigraine effect of ubrogepant 50 mg. Clinical relevance versus statistical significancePeer Tfelt-Hansen, Anika Hüsing, Hans-Christoph Diener
CNS Drugs|November 16, 2013
Animal migraine models for drug development: status and future perspectivesInger Jansen-Olesen, Peer Tfelt-Hansen, Jes Olesen
Pain|July 1, 1989
Intravenous nitroglycerin as an experimental model of vascular headache. Basic characteristicsHelle K Iversen, Jes Olesen, Peer Tfelt-Hansen
Cephalalgia : an International Journal of Headache|August 19, 2021
Doubtful use of placebo following placebo in recent controlled trials of lasmiditan and ubrogepant for the treatment of migraine attacksPeer Tfelt-Hansen, Karsten Jørgensen, Hans-Christoph Diener
British Journal of Clinical Pharmacology|July 9, 2002
The effect of rizatriptan, ergotamine, and their combination on human peripheral arteries: a double-blind, placebo-controlled, crossover study in normal subjectsPeer Tfelt-Hansen, Kaj Seidelin, Michael Stepanavage, et al.
Cephalalgia : an International Journal of Headache|September 25, 2019
Problematic presentation and use of efficacy measures in current trials of CGRP monoclonal antibodies for episodic migraine prevention: A mini-reviewPeer Tfelt-Hansen, Hans-Christoph Diener, Timothy J Steiner
Pageof 11

Showing results (71-80 of 110) with videos related to

Sort By:
Pageof 11
Pharmacology Research & Perspectives|July 15, 2015
The putative P-gp inhibitor telmisartan does not affect the transcellular permeability and cellular uptake of the calcium channel antagonist verapamil in the P-glycoprotein expressing cell line MDCK II MDR1Lasse Saaby, Peer Tfelt-Hansen, Birger Brodin
Ugeskrift for Laeger|October 23, 2008
[Clinical symptoms and pathophysiology of migraine]Peer Tfelt-Hansen, Messoud Ashina, Jes Olesen
Headache|May 22, 2009
Cluster headache and auraKarl Ekbom, Elisabet Waldenlind, Peer Tfelt-Hansen
The Journal of Headache and Pain|May 15, 2007
Contractile responses to ergotamine and dihydroergotamine in the perfused middle cerebral artery of ratPeer Tfelt-Hansen, Elisabeth Nilsson, Lars Edvinsson
Cephalalgia : an International Journal of Headache|May 13, 2021
Critique of the analysis of the time course for the antimigraine effect of ubrogepant 50 mg. Clinical relevance versus statistical significancePeer Tfelt-Hansen, Anika Hüsing, Hans-Christoph Diener
CNS Drugs|November 16, 2013
Animal migraine models for drug development: status and future perspectivesInger Jansen-Olesen, Peer Tfelt-Hansen, Jes Olesen
Pain|July 1, 1989
Intravenous nitroglycerin as an experimental model of vascular headache. Basic characteristicsHelle K Iversen, Jes Olesen, Peer Tfelt-Hansen
Cephalalgia : an International Journal of Headache|August 19, 2021
Doubtful use of placebo following placebo in recent controlled trials of lasmiditan and ubrogepant for the treatment of migraine attacksPeer Tfelt-Hansen, Karsten Jørgensen, Hans-Christoph Diener
British Journal of Clinical Pharmacology|July 9, 2002
The effect of rizatriptan, ergotamine, and their combination on human peripheral arteries: a double-blind, placebo-controlled, crossover study in normal subjectsPeer Tfelt-Hansen, Kaj Seidelin, Michael Stepanavage, et al.
Cephalalgia : an International Journal of Headache|September 25, 2019
Problematic presentation and use of efficacy measures in current trials of CGRP monoclonal antibodies for episodic migraine prevention: A mini-reviewPeer Tfelt-Hansen, Hans-Christoph Diener, Timothy J Steiner
Pageof 11